Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-05-18

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1158/1078-0432.CCR-10-0054PMID 20484020PMCID PMC3907942
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

  2009cited by this paper
• Reciprocal Human Dendritic Cell–Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus1

  2009cited by this paper
• Novel targeted radiosensitisers in cancer treatment.

  2009cited by this paper
• Exploiting synergies between radiation and oncolytic viruses.

  2008cited by this paper
• A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

  2008cited by this paper
• Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

  2008cited by this paper
• Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity1

  2008cited by this paper
• Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

  2008cited by this paper
• Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

  2008cited by this paper
• Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

  2008cited by this paper
• A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

  2008cited by this paper
• Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

  2008cited by this paper
• Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting?

  2007cited by this paper
• Reovirus and other oncolytic viruses for the targeted treatment of cancer

  2006cited by this paper
• Oncolytic viral therapies – the clinical experience

  2005cited by this paper
• Prevalence of Reovirus-Specific Antibodies in Young Children in Nashville, Tennessee

  2005cited by this paper
• Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: Racine and Nonhuman Primates

  2004cited by this paper
• Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals

  2004cited by this paper
• The RAS signal transduction pathway and its role in radiation sensitivity

  2003influential reference
• Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.

  2003cited by this paper
• The epidermal growth factor receptor mediates radioresistance.

  2003cited by this paper
• Interactions between ionizing radiation and drugs in head and neck cancer: how can we maximize the therapeutic index?

  2002cited by this paper
• Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.

  2002cited by this paper
• Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment.

  1999cited by this paper
• The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.

  1996cited by this paper
• Reovirus infections in human volunteers.

  1963cited by this paper

• Arboviruses in Cancer therapy: pros and cons

  2026cites this paper
• Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial

  2025cites this paper
• Advances in preclinical and clinical studies of oncolytic virus combination therapy

  2025cites this paper
• Oncolytic virus and immunogenic cell death in cancer therapy

  2025cites this paper
• Reovirus oncolysis and the next frontiers for this unique oncoviral immunotherapy.

  2025cites this paper
• A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses

  2025cites this paper
• The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models

  2025cites this paper
• Sequence polymorphisms in the reovirus σ1 attachment protein modulate encapsidation efficiency and replication in mice

  2024cites this paper
• Oscillations in a Spatial Oncolytic Virus Model

  2024cites this paper
• Sequences at gene segment termini inclusive of untranslated regions and partial open reading frames play a critical role in mammalian orthoreovirus S gene packaging

  2024cites this paper
• Molecular insights and promise of oncolytic virus based immunotherapy.

  2024cites this paper
• Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.

  2023cites this paper
• Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy

  2023cites this paper
• Developing Oncolytic Viruses for the Treatment of Cervical Cancer

  2023cites this paper
• Sequences at gene segment termini inclusive of untranslated regions and partial open reading frames play a critical role in mammalian orthoreovirus S gene packaging

  2023cites this paper
• Oncolytic Virus-Driven Biotherapies from Bench to Bedside.

  2023cites this paper
• Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages

  2023cites this paper
• Oncolytic viruses in immunotherapy

  2022cites this paper
• Cancer vaccines: the next immunotherapy frontier

  2022cites this paper
• Combining oncolytic virus and radiation therapy for cancer management

  2022influential citation
• Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements

  2021cites this paper
• The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors

  2021cites this paper
• Supplemental Online Content

  2021cites this paper
• Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer.

  2021cites this paper
• Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments.

  2021cites this paper
• Oncolytic Virotherapy for Cancer: Clinical Experience

  2021cites this paper
• Current strategies of virotherapy in clinical trials for cancer treatment

  2021cites this paper
• Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer

  2020cites this paper
• Clinical Application of Oncolytic Viruses: A Systematic Review

  2020cites this paper
• Oncolytic Viruses as Immunotherapeutic Agents

  2020cites this paper
• Clinical landscape of oncolytic virus research in 2020

  2020cites this paper
• Cytokine and Growth Factor Determinants of the efficacy of viro-immunotherapy: A review

  2020cites this paper
• Recent advances of oncolytic virus in cancer therapy

  2020cites this paper
• Past, Present and Future of Oncolytic Reovirus

  2020cites this paper
• Synergistic Suppression Effect on Tumor Growth of Colorectal Cancer by Combining Radiotherapy With a TRAIL-Armed Oncolytic Adenovirus

  2019cites this paper
• Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.

  2019cites this paper
• REOVIRUS-DRIVEN MYELOID CELLS IN ONCOLYTIC VIRUS THERAPY AND INFECTION

  2018cites this paper
• Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy

  2018cites this paper
• Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours

  2018cites this paper
• Virotherapies in Pancreatic Cancer

  2018cites this paper
• Herpes Simplex Virus Type 1 for Use in Cancer Gene Therapy: Looking Backward to Move Forward

  2018cites this paper
• African Swine Fever Virus NP868R Capping Enzyme Promotes Reovirus Rescue during Reverse Genetics by Promoting Reovirus Protein Expression, Virion Assembly, and RNA Incorporation into Infectious Virions

  2017cites this paper
• Herpes Simplex Virus Type 1 for Use in Cancer Gene Therapy : Looking Backward to Move

  2017cites this paper
• Review: Oncolytic virotherapy, updates and future directions

  2017cites this paper
• Evolution of Reovirus in Cancer Therapy

  2017cites this paper
• Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma

  2017cites this paper
• The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies

  2017cites this paper
• Review: Oncolytic Virotherapy, updates and future directions.

  2017cites this paper
• Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus

  2017cites this paper
• Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer

  2017cites this paper
• Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

  2016cites this paper
• Investigational drugs for head and neck cancer

  2016cites this paper
• Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis

  2016cites this paper
• Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses

  2016cites this paper
• Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling

  2016cites this paper
• Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.

  2016cites this paper
• Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus

  2016cites this paper
• Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

  2016cites this paper
• Clinical trials of image‐guided interventions including radiotherapy studies

  2016cites this paper
• Optimising Reovirus Type 3 Dearing (Reolysin®) as an anti-cancer therapeutic

  2016cites this paper
• A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report

  2015cites this paper
• Studies on inducible alphavirus-based antitumour strategy mediated by site-specific delivery with activatable cell-penetrating peptides

  2015cites this paper
• Targeting cancer with reovirus.

  2015cites this paper
• Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants

  2015cites this paper
• Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment

  2015cites this paper
• Oncolytic virotherapy for head and neck cancer: current research and future developments

  2015cites this paper
• KALLE PÄRN Studies on inducible alphavirus-based antitumour strategy mediated by site-specific delivery with activatable cell-penetrating peptides

  2015cites this paper
• Oncolytic virotherapy for head and neck cancer: current research and future developments

  2015cites this paper
• Oncolytic virotherapy for head and neck cancer: current research and future developments

  2015cites this paper
• Oncolytic virotherapy for head and neck cancer: current research and future developments

  2015cites this paper
• Gene Therapy of Solid Cancers

  2015cites this paper
• Oncolytic Viral Therapy Using Reovirus.

  2015cites this paper
• Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

  2015cites this paper
• Naturally occurring reoviruses for human cancer therapy

  2015cites this paper
• Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia

  2015cites this paper
• Reduction of Virion-Associated σ1 Fibers on Oncolytic Reovirus Variants Promotes Adaptation toward Tumorigenic Cells

  2015cites this paper
• A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma

  2014cites this paper
• Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling

  2014cites this paper
• Design and Development of a Robotized System Coupled to µCT Imaging for Intratumoral Drug Evaluation in a HCC Mouse Model

  2014cites this paper
• Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

  2014cites this paper
• Low pathogenic human enteroviruses as novel anti-cancer agents against malignant glioma

  2014cites this paper
• Reovirus in cancer therapy: an evidence-based review

  2014cites this paper
• Going viral with cancer immunotherapy

  2014cites this paper
• Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

  2014cites this paper
• Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

  2014cites this paper
• Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature

  2014cites this paper
• The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice.

  2013cites this paper
• Gene therapy for cancer treatment

  2013cites this paper
• Combination of fractionated irradiation with anti‐VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium

  2013cites this paper
• New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology

  2013cites this paper
• The Impact of the Myeloid Response to Radiation Therapy

  2013cites this paper
• Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites

  2013cites this paper
• The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

  2013cites this paper
• REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

  2013influential citation
• Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis

  2013cites this paper
• Molecular Mechanisms of Reovirus Oncolysis

  2013cites this paper
• Reoviral Therapy for Cancer

  2013cites this paper
• A Novel Therapy for Melanoma and Prostate Cancer Using a Non-Replicating Sendai Virus Particle (HVJ-E)

  2013cites this paper
• Optimisation de la radiovirothérapie en associant un traitement radio-isotopique vectorisé par un virus de la rougeole oncolytique, une radiothérapie externe et une inhibition de checkpoint kinase-1

  2013cites this paper
• Reovirus: A Targeted Therapeutic—Progress And Potential

  2012cites this paper